Manager TitleAgeSince
Investor Relations Contact - -
Corporate Officer/Principal - 10/04/2023
Date Insider Type Main position Quantity % Market Cap.
10/23/10Free

Executive/Senior Manager

4,00,000 0.6684%
01/23/01Free

Chief Operating Officer

4,00,000 0.6686%
01/23/01Free

Chief Financial Officer

4,00,000 0.6686%
Change 5-day change 1-year change 3-year change Capi.($)
-13.39%-23.18% - - 29.5L
+1.84%-0.66%+59.82%+92.96% 5.49TCr
-4.14%-8.06%+58.96%+118.67% 5.46TCr
-2.24%+3.59%+17.75%+477.47% 2.51TCr
-1.60%-6.21%-18.96%-15.21% 2.31TCr
+2.43%+1.06%+42.44%-1.27% 1.99TCr
-3.19%0.00%+35.60%-26.98% 1.75TCr
-6.84%+2.18%+195.12%+357.18% 1.65TCr
+8.74%+3.51%+51.91%+726.40% 1.57TCr
-1.05%+1.16%+25.95%+194.27% 1.42TCr
Average -1.94%-0.28%+52.07%+213.72% 2.68TCr
Weighted average by Cap. -0.90%-1.45%+51.26%+177.14%
Logo Aravive, Inc.
Aravive, Inc. is a clinical-stage oncology company. The Company is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The Company's lead product candidate, Batiraxcept, is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase III trial in platinum-resistant ovarian cancer (NCT04729608), a Phase Ib/II trial in clear cell renal cell carcinoma (NCT04300140), and a Phase Ib/II trial in pancreatic adenocarcinoma (NCT04983407).
Employees
23
  1. Stock Market
  2. Stocks
  3. ARAV Stock